No Data
No Data
B.Riley Financial Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $4
Analysts Conflicted on These Healthcare Names: Lemaitre Vascular (LMAT), Catalyst Pharma (CPRX) and Nektar Therapeutics (NKTR)
Express News | Nektar Therapeutics Announces Completion of Target Enrollment in Rezolve-Aa Phase 2B Clinical Trial of Rezpegaldesleukin in Patients With Severe-to-Very Severe Alopecia Areata
BTIG Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $4
A Quick Look at Today's Ratings for Nektar Therapeutics(NKTR.US), With a Forecast Between $6.5 to $7
Express News | HC Wainwright & Co. Reiterates Buy on Nektar Therapeutics, Maintains $6.5 Price Target